80%Confidence
0Views
FDASource
2026-03-17Date
Summary
Rising Pharma's Temozolomide stability failure reveals quality control gaps in their oncology portfolio, potentially affecting this critical brain cancer treatment's availability. The Taiwan manufacturing origin suggests possible geographic quality consistency issues that could impact Rising's broader product pipeline.
Actionable: Review stability data for other Rising Pharma products and consider increasing inventory buffers for Temozolomide.
AI Confidence: 80%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now